Philippe Ferber

780 total citations
29 papers, 546 citations indexed

About

Philippe Ferber is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Immunology. According to data from OpenAlex, Philippe Ferber has authored 29 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 8 papers in Immunology. Recurrent topics in Philippe Ferber's work include Lipoproteins and Cardiovascular Health (7 papers), Blood Pressure and Hypertension Studies (6 papers) and Atherosclerosis and Cardiovascular Diseases (5 papers). Philippe Ferber is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Blood Pressure and Hypertension Studies (6 papers) and Atherosclerosis and Cardiovascular Diseases (5 papers). Philippe Ferber collaborates with scholars based in Switzerland, Germany and United Kingdom. Philippe Ferber's co-authors include Joseph L. Izzo, Yves Allemann, Michaela Barbier, Giancarlo Viberti, Vincenzo Mirenda, Andrew H. Smith, Albert Kandra, Jaco Botha, Janaka Karalliedde and Giuseppe Palermo and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Journal of the American College of Cardiology.

In The Last Decade

Philippe Ferber

26 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Ferber Switzerland	12	366	191	105	51	49	29	546
Mojca Lunder Slovenia	14	292 0.8×	169 0.9×	137 1.3×	39 0.8×	99 2.0×	41	553
Miodrag Janić Slovenia	14	315 0.9×	164 0.9×	135 1.3×	39 0.8×	107 2.2×	47	575
Seiko Manabe Japan	11	252 0.7×	108 0.6×	110 1.0×	22 0.4×	95 1.9×	14	472
C. Ian Doris Canada	3	355 1.0×	155 0.8×	105 1.0×	94 1.8×	119 2.4×	6	576
Ryu Kobayashi Japan	15	227 0.6×	162 0.8×	81 0.8×	43 0.8×	44 0.9×	42	521
Fabrice M A C Martens Netherlands	10	200 0.5×	221 1.2×	137 1.3×	36 0.7×	40 0.8×	25	609
Atheline Major‐Pedersen Denmark	14	318 0.9×	271 1.4×	110 1.0×	74 1.5×	22 0.4×	23	635
Toru Dejima Japan	15	397 1.1×	187 1.0×	79 0.8×	53 1.0×	21 0.4×	27	580
Tomohiko Kanaoka Japan	17	345 0.9×	226 1.2×	119 1.1×	50 1.0×	60 1.2×	51	706
Stanislav Oravec Slovakia	16	124 0.3×	217 1.1×	219 2.1×	77 1.5×	55 1.1×	46	611

Countries citing papers authored by Philippe Ferber

Since Specialization

Citations

This map shows the geographic impact of Philippe Ferber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Ferber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Ferber more than expected).

Fields of papers citing papers by Philippe Ferber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Ferber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Ferber. The network helps show where Philippe Ferber may publish in the future.

Co-authorship network of co-authors of Philippe Ferber

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Ferber. A scholar is included among the top collaborators of Philippe Ferber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Ferber. Philippe Ferber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Julius, Ulrich, Thilo Krüger, Julia Weinmann‐Menke, et al.. (2026). Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. European Heart Journal.

Enamullah, Mohammed, et al.. (2025). Dinuclear vs. mononuclear copper( ii ) complexes with nitrophenylimino-benzylal- vs. -naphthylal-based Schiff base ligands. New Journal of Chemistry. 49(39). 17106–17123.

Enamullah, Mohammed, et al.. (2025). Square planar vs. pyramidal copper(ii)-complexes with benzylal vs. naphthylal-based Schiff bases. RSC Advances. 15(23). 18358–18371. 1 indexed citations

Leistner, David M., Andrés Laguna-Fernández, Arash Haghikia, et al.. (2024). Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity. European Journal of Preventive Cardiology. 31(7). 856–865. 23 indexed citations

Latour, Régis Peffault de, Austin Kulasekararaj, Phillip Scheinberg, et al.. (2024). The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial. Blood. 144(Supplement 1). 4087–4087.

Welsh, Paul, Harriet R. Benbow, Madlaina Costa‐Scharplatz, et al.. (2023). Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank. Atherosclerosis. 389. 117437–117437. 17 indexed citations

Maggioni, Aldo P., Andrew L. Clark, Vivencio Barrios, et al.. (2022). Outcomes with Sacubitril/Valsartan in Outpatients with Heart Failure and Reduced Ejection Fraction: The ARIADNE Registry. ESC Heart Failure. 9(6). 4209–4218. 7 indexed citations

Lund, Lars H., Uwe Zeymer, Andrew L. Clark, et al.. (2022). Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry. International Journal of Cardiology. 370. 279–286. 3 indexed citations

Lahoz, Raquel, et al.. (2021). LP(A) DISTRIBUTION AND CORRELATION WITH LDL-C IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) IN THE US. Journal of the American College of Cardiology. 77(18). 1564–1564. 2 indexed citations

10.

Zeymer, Uwe, Andrew L. Clark, Vivencio Barrios, et al.. (2021). Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. European Heart Journal - Quality of Care and Clinical Outcomes. 8(4). 469–477. 11 indexed citations

11.

Piepoli, Massimo, Rizwan I. Hussain, Josep Comín‐Colet, et al.. (2020). OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure. 23(1). 127–135. 56 indexed citations

12.

Lahoz, Raquel, et al.. (2020). Characteristics of patients with at least one lipoprotein(a) [Lp(a)] assessment and those with Lp(a) levels equal to or greater than 70 mg/dL: a real-world study in the US. European Heart Journal. 41(Supplement_2). 1 indexed citations

13.

Bogman, Katrijn, Dietmar Schwab, Marie‐Laure Delporte, et al.. (2016). Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 69(1). 189–196. 78 indexed citations

14.

Teixeira, Priscila Camillo, Axel Ducret, Philippe Ferber, et al.. (2014). Definition of Human Apolipoprotein A-I Epitopes Recognized by Autoantibodies Present in Patients with Cardiovascular Diseases. Journal of Biological Chemistry. 289(41). 28249–28259. 22 indexed citations

15.

Allemann, Yves, et al.. (2008). Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX‐FAST) Study. Journal of Clinical Hypertension. 10(3). 185–194. 89 indexed citations

16.

Баранова, Е. И., et al.. (2008). Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: A multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study. Clinical Therapeutics. 30(10). 1782–1793. 2 indexed citations

17.

Roesen, P., et al.. (2003). Genetic variation of the platelet- surface integrin GPIIb-IIIa ( PIA1/A2- SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia. 46(7). 984–989. 15 indexed citations

18.

Roesen, P., Philippe Ferber, & D. Tschoepe. (2001). Macrovascular disease in diabetes: current status. Experimental and Clinical Endocrinology & Diabetes. 109(Suppl 2). S474–S486. 8 indexed citations

19.

Ferber, Philippe, et al.. (1999). High Dose Supplementation of RRR-α-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus. Hormone and Metabolic Research. 31(12). 665–671. 8 indexed citations

20.

Weber, P.C., Philippe Ferber, R. Fischer, Kaspar H. Winterhalter, & Lloyd Vaughan. (1996). Binding of contactin/F11 to the fibronectin type III domains 5 and 6 of tenascin is inhibited by heparin. FEBS Letters. 389(3). 304–308. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact